Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Alexander

Showing results (111-120 of 114) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 114 results.
BMC Medicine|March 3, 2022
Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variantMaren Schubert, Federico Bertoglio, Stephan Steinke, et al.
Nature Communications|March 12, 2021
SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interfaceFederico Bertoglio, Doris Meier, Nora Langreder, et al.
Cell Reports|July 17, 2021
A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutationsFederico Bertoglio, Viola Fühner, Maximilian Ruschig, et al.
Lancet (London, England)|July 17, 2025
Surgical health policy 2025-35: strengthening essential services for tomorrow's needsDmitri Nepogodiev, Maria Picciochi, Adesoji Ademuyiwa, et al.
Pageof 12

Showing results (111-120 of 114) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 114 results.
BMC Medicine|March 3, 2022
Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variantMaren Schubert, Federico Bertoglio, Stephan Steinke, et al.
Nature Communications|March 12, 2021
SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interfaceFederico Bertoglio, Doris Meier, Nora Langreder, et al.
Cell Reports|July 17, 2021
A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutationsFederico Bertoglio, Viola Fühner, Maximilian Ruschig, et al.
Lancet (London, England)|July 17, 2025
Surgical health policy 2025-35: strengthening essential services for tomorrow's needsDmitri Nepogodiev, Maria Picciochi, Adesoji Ademuyiwa, et al.
Pageof 12